AIM： To explore the feasibility of local interleukin 2 （IL-2） in patients with different forms of abdominal cancer. This required experimentation with the time interval between IL-2 applications and the methods of ...AIM： To explore the feasibility of local interleukin 2 （IL-2） in patients with different forms of abdominal cancer. This required experimentation with the time interval between IL-2 applications and the methods of application. METHODS： Sixteen patients with stages Ⅲ and Ⅳ of gastrointestinal malignancies （primary or metastatic） who were admitted to our Department of Gastroenterology were treated with Iocoregionally applied IL-2 in low doses. RESULTS： No major problems applying Iocoregional IL-2 were encountered. In 6 out of 16 patients, a modest but clinically worthwhile improvement was obtained. Adverse effects were minimal. The therapeutic scheme was well tolerated, even in patients in a poor condition. CONCLUSION： This study demonstrates the feasibility of low dose Iocoregional IL-2 application in advanced abdominal cancer. Local IL-2 therapy gives only negligible adverse effects. The results suggest that it is important to apply intratumorally. Local IL-2 may be given adjunct to standard therapeutic regimes and does not imply complex surgical interventions. These initial results are encouraging.展开更多
文摘AIM： To explore the feasibility of local interleukin 2 （IL-2） in patients with different forms of abdominal cancer. This required experimentation with the time interval between IL-2 applications and the methods of application. METHODS： Sixteen patients with stages Ⅲ and Ⅳ of gastrointestinal malignancies （primary or metastatic） who were admitted to our Department of Gastroenterology were treated with Iocoregionally applied IL-2 in low doses. RESULTS： No major problems applying Iocoregional IL-2 were encountered. In 6 out of 16 patients, a modest but clinically worthwhile improvement was obtained. Adverse effects were minimal. The therapeutic scheme was well tolerated, even in patients in a poor condition. CONCLUSION： This study demonstrates the feasibility of low dose Iocoregional IL-2 application in advanced abdominal cancer. Local IL-2 therapy gives only negligible adverse effects. The results suggest that it is important to apply intratumorally. Local IL-2 may be given adjunct to standard therapeutic regimes and does not imply complex surgical interventions. These initial results are encouraging.
